In a report released yesterday, Evan Seigerman from BMO Capital reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a price target of $145.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evan Seigerman has given his Buy rating due to a combination of factors tied to aleniglipron’s emerging profile and market positioning. Forty‑four‑week Phase 2b data show that the 180 mg dose delivers over 16% placebo‑adjusted weight loss with no clear plateau, which he views as meaningfully competitive versus other oral GLP‑1 candidates such as orforglipron and Novo Nordisk’s Wegovy pill.
Seigerman also notes that the Phase 2 program is effectively defining the optimal dose for Phase 3, with similar efficacy between 180 mg and 240 mg suggesting a clear, efficient path forward. While discontinuations from adverse events have appeared, they remain limited and may be mitigated through slower titration strategies seen in the ACCESS OLE study. Combined with strong incremental data from extension studies and a large unmet need for convenient, lower‑cost obesity drugs, he expects the shares to respond positively and maintains an Outperform stance on GPCR.
Seigerman covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Vertex Pharmaceuticals, and Disc Medicine. According to TipRanks, Seigerman has an average return of 8.3% and a 52.24% success rate on recommended stocks.
In another report released yesterday, Citi also reiterated a Buy rating on the stock with a $100.00 price target.